Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

TipRanks

Tue, Nov 19, 2024, 5:27 AM 1 min read

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $21 from $32 and keeps an Equal Weight rating on the shares. Q3 results came in slightly above the preliminary view as average selling price strength more than offset some volume softness, the analyst noted. UnitedHealth’s (UNH) decision to drop coverage of multi-gene behavioral health PGx tests equates annually to about $40M in revenue and about $30M in gross profit impact, notes the analyst, who adds that “broader payor fallout bears watching.”

Don't Miss out on Research Tools:

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on MYGN: